NCT04144842View on ClinicalTrials.gov

Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions
Solid TumorNeoplasms
Interventions
BIOLOGICAL

ATOR-1017

ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)

Trial Locations (3)

SE-221 85

Department of Oncology, Skåne University Hospital, Lund

SE-171 64

Fas 1-enheten, Centrum för Kliniska Cancerstudier, Karolinska Universitetssjukhuset, Solna

SE-751 85

Department of Oncology, Uppsala University Hospital, Uppsala

Sponsors
All Listed Sponsors
lead

Alligator Bioscience AB

INDUSTRY

NCT04144842 - Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017 | Biotech Hunter | Biotech Hunter